Vantictumab Antibody
Vantictumab (OMP-18R5) is a humanized monoclonal antibody targeting FZD receptors 1, 2, 5, 7, and 8 to inhibit Wnt signaling. It is utilized in preclinical research for metastatic HER2-negative breast cancer and pancreatic adenocarcinoma, with studies demonstrating its activity in both in vitro models and in vivo xenograft experiments.
Product Specifications
Product Name Alternative
Bcatenin, beta-catenin, betacatenin, OMP18R5, βcatenin, Wnt/betacatenin, Wnt/b-catenin, Wnt, Wnt/β-catenin
Target
Wnt/beta-catenin
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Signal Transduction, Stem Cell & Developmental Biology
Concentration
6.05 mg/mL
Purity
97.70% (May vary between batches)
Molecular Weight
142.69 kDa
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
EPM2A (Laforin, Lafora PTPase, LAFPTPase, EPM2) (AP) discontinued
SMARCD3 (NM_001003802) Human Over-expression Lysate
